Delta-Fly Pharma, Inc. (4598) Other
Market cap
¥1.8B
P/E ratio
-1.6x
Delta-Fly Pharma develops cancer treatments using a unique "modular drug discovery" approach that builds new drugs from existing cancer-fighting compounds.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Return on Assets | - | - | - | - | -7.7 | -11.3 | -4.1 | -7.4 | -26 | -38.3 | -43.3 | -110.7 |
| Return on equity (%) | - | - | - | |||||||||
| Employees | 5 | 5 | 8 | 11 | 11 | 13 | 11 | 12 | 11 | 13 | 13 | - |